Vera Therapeutics CEO exercises options and sells shares
Vera Therapeutics, Inc. reported that President and CEO Marshall Fordyce exercised stock options for 18,500 shares of Class A Common Stock on May 12, 2026 at an exercise price of $2.8968 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4/A
Rhea-AI Filing Summary
Vera Therapeutics, Inc. reported that President and CEO Marshall Fordyce exercised stock options for 18,500 shares of Class A Common Stock on May 12, 2026 at an exercise price of $2.8968 per share. The option exercise left 590,551 stock options outstanding under this award. On the same date, he sold 18,500 shares of Class A Common Stock in open-market transactions, including 14,219 shares at a weighted-average price of $36.6396 and 4,281 shares at a weighted-average price of $37.0868. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on January 9, 2026.
Insider Trade Summary 10b5-1
Exercise and Sale: 18,500 shares ($626K approx. pre-tax spread)
Exercise and Sale
4 txns
Insider
Fordyce Marshall
Role
PRESIDENT AND CEO
Sold
18,500 shs ($680K)
Approx. gross sale proceeds
$680K
Approx. exercise cost
$54K
Approx. pre-tax spread
$626K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F5 | 18,500 | $0.00 | $0.00 |
| Exercise | Class A Common Stock F1 | 18,500 | $2.8968 | $54K |
| Sale | Class A Common Stock F2, F3, F1 | 14,219 | $36.6396 | $521K |
| Sale | Class A Common Stock F2, F4, F1 | 4,281 | $37.0868 | $159K |
Holdings After Transaction:
Stock Option (Right to Buy) — 590,551 contracts (Direct);
Class A Common Stock — 235,244 shares (Direct)
Footnotes (5)
- F1. This amended Form 4 is filed to reflect the option exercise that occurred on May 12, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)".
- F2. The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- F3. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.96 to $36.94, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F4. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $36.97 to $37.15, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F5. 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter.
Key Figures
Options exercised: 18,500 shares
Exercise price: $2.8968 per share
Shares sold (first tranche): 14,219 shares at $36.6396
+5 more
8 metrics
Options exercised
18,500 shares
Stock options for Class A Common Stock exercised on May 12, 2026
Exercise price
$2.8968 per share
Exercise price of stock options converted into Class A Common Stock
Shares sold (first tranche)
14,219 shares at $36.6396
Weighted-average sale price for first set of Class A Common Stock sales
Shares sold (second tranche)
4,281 shares at $37.0868
Weighted-average sale price for second set of Class A Common Stock sales
Total shares sold
18,500 shares
Aggregate Class A Common Stock sold on May 12, 2026
Remaining options
590,551 options
Stock options beneficially owned following the reported option exercise
Option expiration
December 15, 2030
Expiration date of the stock option from which 18,500 shares were exercised
10b5-1 plan adoption date
January 9, 2026
Date of written trading plan covering the reported stock sales
Key Terms
Rule 10b5-1(c), weighted-average price, stock option, beneficially owned, +1 more
5 terms
Rule 10b5-1(c) regulatory
"plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c)"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
weighted-average price financial
"The price reported is a weighted-average price. These shares were sold"
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
stock option financial
"Stock Option (Right to Buy) with an exercise price of $2.8968"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
beneficially owned regulatory
"correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Class A Common Stock financial
"underlying security title is Class A Common Stock for the option exercise"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Vera Therapeutics (VERA) CEO Marshall Fordyce report in this amended Form 4?
Marshall Fordyce reported exercising options for 18,500 shares of Class A Common Stock at $2.8968 per share and selling 18,500 shares in open-market transactions on May 12, 2026 under a Rule 10b5-1 plan.
Were Marshall Fordyce’s Vera Therapeutics (VERA) stock sales under a Rule 10b5-1 plan?
Yes. The filing states the sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) under the Securities Exchange Act of 1934.
What stock option activity did Vera Therapeutics (VERA) disclose for its CEO?
Marshall Fordyce exercised stock options for 18,500 shares of Class A Common Stock at an exercise price of $2.8968 per share, and after this transaction 590,551 stock options under that award remained outstanding.
Why was this Vera Therapeutics (VERA) Form 4 amended?
The amendment was filed to reflect the option exercise on May 12, 2026 and to correct the amounts reported in Column 5 for the securities beneficially owned following the reported transactions.
How are the sale prices described for the Vera Therapeutics (VERA) CEO’s transactions?
Each sale line reports a weighted-average price: 14,219 shares between $35.96–$36.94, and 4,281 shares between $36.97–$37.15. The CEO will provide detailed per-trade prices to regulators or shareholders upon request.
AI-generated analysis. How Rhea-AI works. Not financial advice.
